KOSDAQ

Brainzcompany Co., Ltd.’s Subsidiary, Afreeca, Participates in the AI Summit in Seoul

Enterprise AI Platform Unveiled

Hyera Lee
2026-07-21 08:43:16
[Edaily Reporter Hyera Lee ] Brainzcompany Co., Ltd.(099390)announced on the 21st that its subsidiary, AfricA, will participate in the “AI Summit Seoul & Expo 2026” (AISE 2026), to be held next month, to showcase an integrated platform for the development and operation of enterprise AI agents designed for corporate environments.
AfricA CI. (Photo courtesy of Brainzcompany Co., Ltd.)

The company plans to introduce a platform capable of comprehensively managing the entire process—from AI model development to LLM operations, agent creation, and tool integration—required to apply AI agents to real-world work.
AfricA will unveil an integrated platform based on “Cheetah,” its AI model and LLM development and operations platform, and “Serengeti AI Agent Studio,” its AI Agent creation and tool integration platform.
Cheetah supports data preparation, model training and evaluation, deployment, GPU and NPU resource management, and LLM service operations through MLOps and LLMOps. Serengeti AI Agent Studio supports everything from AI agent creation to tool integration, deployment, and operations, providing an operational environment for AI agents that perform actual business tasks by connecting a company’s internal knowledge, business systems, and APIs.
A company representative stated, “At AISE 2026, we plan to showcase the capabilities of our enterprise AI platform, which integrates AI model development, LLM operations, agent creation, and tool integration into a single workflow.”

Economy

Corporation

IT·Science

Economy

"Semiconductors Competing on the Global Stage… R&D Needs Relaxation of the '52-Hour Workweek Rule'"

“Regulations on the 52-hour workweek should be relaxed for businesses that create new concepts or for semiconductor research and development (R&D).”KoreaInformation&Communication Technology Promotion …
2026-08-13 19:30:52

Corporation

Injenia’s Enterprise Value Set to Grow Further After Listing… Backed by Three Major Positive Factors, Including Technology Exports

Ingenia Therapeutics (hereinafter “Ingenia”), a developer of new antibody drugs for microvascular diseases set to list on the KOSDAQ market on the 18th, is expected to show steep growth following a re…
2026-08-14 08:31:02

IT·Science

Royvant Bets on Hanol’s IMVT-1402… “GD New Drug to Launch Ahead of Competitors”

Royvant is focusing its funding and development capabilities on IMVT-1402 (active ingredient: imeropruvate), a next-generation FcRn antibody licensed from HANALL BIOPHARMA CO.,LTD(009420). This comes …
2026-08-14 08:36:02